| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/28/2010 | CN1814292B Anti-cancer prodrug, preparing method and use |
| 04/28/2010 | CN1753968B Antioxidative composition and composition for external use |
| 04/28/2010 | CN1717252B Preparation containing basic drug |
| 04/28/2010 | CN1700917B Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| 04/28/2010 | CN1679403B Fat or oil processing food |
| 04/28/2010 | CN1668359B Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs |
| 04/28/2010 | CN1662260B Process for producing sustained-release composition |
| 04/28/2010 | CN1652698B Method and dietary composition for improving lipid digestibility |
| 04/28/2010 | CN1652697B Method and dietary composition for improving fat digestibility |
| 04/28/2010 | CN1652696B Method of improving absorption of vitamin E by a pet animal |
| 04/28/2010 | CN1620284B Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tool for producing it |
| 04/28/2010 | CN1596266B Specific binding agents of human angiopoietin-2 |
| 04/28/2010 | CN1556705B 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives |
| 04/28/2010 | CN1524579B Composite viscoelastic preparation |
| 04/28/2010 | CN1468307B Anti-dual integrin antibodies, compositions, methods and uses |
| 04/28/2010 | CN1443085B Method for locating compounds which are suitable for treatment and/or prophylaxis of obesity |
| 04/28/2010 | CN1416335B New self emulsifying drug delivery system |
| 04/28/2010 | CN101698103A Medicine composite for treating B type diabetes |
| 04/28/2010 | CN101698102A Ultra-potent composite for decontaminating hazardous chemical substances |
| 04/28/2010 | CN101698101A Medicine composite for treating vaginitis |
| 04/28/2010 | CN101698007A Medicine for treating aphtha |
| 04/27/2010 | USRE41288 increasing insulinotropic response in ischemia and treating reperfusion and injured brain cells after an ischemic event by administering glucagon-like peptide-1 and a pharmaceutical carrier for a time sufficient and under conditions effective to increase insulinotropic response which produces insulin |
| 04/27/2010 | US7705196 sFRP expression enhancing agent |
| 04/27/2010 | US7705195 Screening method |
| 04/27/2010 | US7705039 Method for treating sleep apnea |
| 04/27/2010 | US7704987 Metal complex based on 1,10-phenanthroline binds to histidine of the N-terminal loop of the peptide in such a way that the N-terminal loop (amino acid residues 1-15) is blocked or destabilised to inhibit the binding copper, zinc and iron compounds -ones of magnesium /calcium; Alzheimer,s disease |
| 04/27/2010 | US7704979 Materials and methods for the treatment or prevention of obesity |
| 04/27/2010 | US7704978 Methods for treating neuropsychiatric disorders |
| 04/27/2010 | US7704971 Uracil reductase inactivators |
| 04/27/2010 | US7704965 Methods and materials for treating human papillomavirus infections |
| 04/27/2010 | US7704952 treating diabetes or obesity using isolated polypeptide is covalently modified with a water-soluble polymer |
| 04/27/2010 | US7704950 Methods of using soluble heterodimeric cytokine receptor |
| 04/27/2010 | US7704542 Vitamin/mineral compositions with DHA |
| 04/27/2010 | US7704526 Sustained release composition for oral administration of drugs |
| 04/27/2010 | US7704503 methods for screening test compounds capable of inhibiting, i.e., decreasing, limiting, blocking, or otherwise reducing, IL-17F bioactivity, and methods for diagnosing, prognosing, and monitoring the progress of, disorders related to IL-17F bioactivity, e.g., in patients with cystic fibrosis |
| 04/27/2010 | US7704502 Combinations of antibodies selective for DR5 and other therapeutic agents |
| 04/27/2010 | US7704498 Antiproliferative agents; anticancer agents; composition comprising antagonist of a human ErbB4 receptor, in admixture with a pharmaceutically acceptable carrier; antagonist selected from group consisting of an antibody produced by a hybridoma selected from the group containing HER4.10H1.1A1 |
| 04/27/2010 | CA2449180C Viral polymerase inhibitors |
| 04/27/2010 | CA2437524C Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 04/27/2010 | CA2422378C Pyrazole compounds useful as protein kinase inhibitors |
| 04/27/2010 | CA2321951C Dietary control of arachidonic acid metabolism |
| 04/27/2010 | CA2293692C Methods and reagents for vaccination which generate a cd8 t cell immune response |
| 04/27/2010 | CA2278465C Diagnosis and treatment of myocardial failure |
| 04/27/2010 | CA2275657C Endoparasiticidal and ectoparasiticidal agents |
| 04/22/2010 | WO2010045601A2 Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents |
| 04/22/2010 | WO2010045558A1 Method of determining a phosphorus binder dosage for a dialysis patient |
| 04/22/2010 | WO2010044371A1 Insulin secretion stimulator |
| 04/22/2010 | WO2010043029A1 Use of tetrose to inhibit cancer and to increase cell viability |
| 04/22/2010 | WO2010009985A3 Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| 04/22/2010 | WO2009156680A3 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders |
| 04/22/2010 | WO2009107098A3 An oral treatment composition comprising potassium nitrate and hexylene glycol |
| 04/22/2010 | US20100099742 Sensitizing Cells for Apoptosis by Selectively Blocking Cytokines |
| 04/22/2010 | US20100099711 Methods and Compositions Using Immunomodulatory Compounds for The Treatment and Management of Cancers and Other Diseases |
| 04/22/2010 | US20100099656 Neurotherapeutic compositions |
| 04/22/2010 | US20100099647 Aqueous Iron Carbohydrate Complexes, Their Production And Medicaments Containing Them |
| 04/22/2010 | US20100099576 Skin substitutes with improved barrier function |
| 04/22/2010 | US20100098743 Medical substitute membrane, use thereof, and method for repair of membrane tissue in living body |
| 04/22/2010 | US20100098736 Connective tissue repair |
| 04/22/2010 | US20100098678 Methods of Treatment of Mitochondrial Disorders |
| 04/22/2010 | US20100098677 Methods and Devices for Epithelial Protection During Photodynamic Therapy |
| 04/22/2010 | DE202004021680U1 Feste pharmazeutische Zusammensetzung A solid pharmaceutical composition |
| 04/22/2010 | CA2739545A1 Method of determining a phosphorus binder dosage for a dialysis patient |
| 04/21/2010 | EP2177601A1 Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| 04/21/2010 | EP2177513A1 Phenylacetic acid compound |
| 04/21/2010 | EP2177225A1 Peritoneal dialysate |
| 04/21/2010 | EP2177223A2 Homoharringonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to sti571 |
| 04/21/2010 | EP2177222A1 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis |
| 04/21/2010 | EP2176665A1 Tumor cell-derived microvesicles |
| 04/21/2010 | EP2175886A1 Combination methods and compositions for treatment of neuropathic pain |
| 04/21/2010 | EP1909837B1 Compositions for treatment of systemic mastocytosis |
| 04/21/2010 | EP1853270B1 Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| 04/21/2010 | EP1689782B1 Anti-igfr1 antibody therapeutic combinations |
| 04/21/2010 | EP1592388B1 Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin |
| 04/21/2010 | EP1471887B1 Nanoparticulate compositions having lysozyme as a surface stabilizer |
| 04/21/2010 | EP1387685B1 Analgesic composition comprising an opioid and a sodium channel blocker |
| 04/21/2010 | EP1258252B1 Integrin expression inhibitors |
| 04/21/2010 | EP0922102B1 Hepatocyte growth factor receptor agonists and uses thereof |
| 04/21/2010 | EP0870033B1 Integrin-linked kinase, its inhibitors and methods of medical treatment using these inhibitors, gene therapy and pseudo-substrate inhibitors |
| 04/21/2010 | CN1961974B Nano copolymer fibrous membrane material capable of being biodegraded and absorbed and preparation process and use thereof |
| 04/21/2010 | CN1891296B Medicinal composition containing calcium agonist and phenoxy acid compound |
| 04/21/2010 | CN1740169B Arylmethylamine derivatives for use as tryptase inhibitors |
| 04/21/2010 | CN1514725B Pharmaceutical composition comprising lipase inhibitor and sucrose fatty acid ester |
| 04/21/2010 | CN101696232A Peptidomimetic protease inhibitors |
| 04/21/2010 | CN101695575A Pharmaceutical composition containing statin-type lipid-lowering medicaments, phenformin-type hypoglycemic medicaments and nicotinic acid |
| 04/21/2010 | CN101695495A Composition for treatment of external secretion disorders |
| 04/21/2010 | CN101695492A Pharmaceutical composition containing statin-type lipid-lowering medicaments, sulphonylurea-type hypoglycemic medicaments and nicotinic acid |
| 04/21/2010 | CN101695483A Independently controllable contraceptive transdermal patch containing progestogen and estrogen and preparation method thereof |
| 04/21/2010 | CN101695476A Method for preparing medical nanoparticles |
| 04/20/2010 | US7700792 Highly active lysophosphatidic acid and method of screening therewith |
| 04/20/2010 | US7700778 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 04/20/2010 | US7700775 Drug delivery |
| 04/20/2010 | US7700742 Antibodies to insulin-like growth factor I receptor |
| 04/20/2010 | US7700719 Mutant protofibril for active immunisation; synuclein genes, proteins; point mutations; Parkinson's disease; dementia; host cells |
| 04/20/2010 | US7700715 Kit for use in the diagnosis and treatment of cancer |
| 04/20/2010 | US7700615 comprises 4-methyl-3-nitro-benzoic acid as inhibitor and 1,3-bis(2-chloroethyl)-1-nitrosourea as chemotherapeutic agent; for treatment of breast cancer and melanomas |
| 04/20/2010 | US7700610 Use of tyrosine kinase inhibitors for treating allergic diseases |
| 04/20/2010 | US7700583 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| 04/20/2010 | US7700571 Compositions and methods for liver growth and liver protection |
| 04/20/2010 | US7700562 Use of —furin—“convertase” inhibitors in the treatment of fibrosis and scarring |
| 04/20/2010 | US7700558 Methods for treating diabetes using fibroblast growth factor-like polypeptides |